Table 1 Baseline characteristics of the study population
Parameter | Patient groups | |||||
|---|---|---|---|---|---|---|
eGFR at baseline | eGFR decline by 25% at 2 years | |||||
Normal eGFR, ≥ 60 mL/min/1.73 m2 (N = 7) | Low eGFR, < 60 mL/min/1.73 m2 (N = 23) | p | No (N = 23) | Yes (N = 7) | p | |
Recipient age, years | 36 (16–47)a | 38 (29–42) | 0.565 | 36 (24–42) | 38 (27–42) | 0.962 |
Recipient gender, males, n (%) | 2 (28.6) | 14 (60.9) | 0.134 | 13 (56.5) | 3 (42.9) | 0.526 |
Calcineurin inhibitor, cyclosporine A use, n (%) | 5 (71.4) | 13 (56.5) | 0.481 | 15 (65.2) | 3 (42.9) | 0.290 |
Antiproliferative agent, mycophenolate mofetil use, n (%) | 6 (85.7) | 23 (100) | 0.065 | 22 (95.7) | 7 (100) | 0.575 |
Anti-IL-2 receptor antibodies use, n (%) | 5 (71.4) | 15 (65.2) | 0.760 | 17 (73.9) | 3 (42.9) | 0.127 |
Type of donor, deceased, n (%) | 4 (57.1) | 18 (78.3) | 0.269 | 16 (69.6) | 6 (85.7) | 0.398 |
Impaired initial function, n (%) | 1 (14.3) | 6 (26.1) | 0.518 | 4 (17.4) | 3 (42.9) | 0.163 |
Previous AR, n (%) | 0 | 2 (8.7) | 0.419 | 1 (4.4) | 1 (14.3) | 0.356 |
Time after transplantation (months) | 68 (45–128) | 68 (41–102) | 0.848 | 68 (36–84) | 126 (52–156) | 0.096 |
Serum creatinine (µmol/L) | 100 (78–121) | 192 (134–247) | < 0.001 | 136 (115–201) | 202 (137–247) | 0.077 |
eGFR (mL/min/1.73 m2) | 79 (67–91) | 34 (31–46) | < 0.001 | 41 (32–58) | 34 (15–67) | 0.266 |
Serum urea (mmol/L) | 5.8 (5.2–6.4) | 10.4 (8.4–12.7) | < 0.001 | 9.3 (6.8–12.4) | 9.9 (6.1–20.3) | 0.632 |
Proteinuria/creatinine (mg/mmol) | 2.7 (0.9–3.6) | 9.4 (4.0–20.5) | 0.008 | 6.0 (1.5–10.8) | 20.5 (3.3–60.7) | 0.029 |
Proteinuria/creatinine > 15 mg/mmol, n (%) | 0 | 9 (39.1) | 0.048 | 4 (17.4) | 5 (71.4) | 0.006 |
Diuresis (L/day) | 1.4 (1.1–1.6) | 1.4 (1.2–1.7) | 0.811 | 1.4 (1.1–1.5) | 1.6 (1.4–1.7) | 0.033 |
Mean arterial pressure (mm Hg) | 93 (93–103) | 110 (103–116) | 0.001 | 103 (93–116) | 116 (103–116) | 0.288 |
Treated hypertension, n (%) | 1 (14.3) | 14 (60.9) | 0.031 | 10 (43.5) | 5 (71.4) | 0.195 |